Results are reported from the first two adequate trials of the PDE-5 inhibitor vardenafil using a stopwatch to precisely measure erection duration in men with ED. Two randomized, multicenter, double-blind, placebo-controlled trials were conducted: a crossover 4-week treatment in men with ED (ENDURANCE) and a parallel group, 12-week treatment in men with ED and dyslipidemia (the dyslipidemia study). Stopwatch-assessed duration of erection leading to successful intercourse measured by Sexual Encounter Profile question-3 (SEP-3) was the primary end point in ENDURANCE and one of the secondary end points in the dyslipidemia study. Other efficacy end points included responses to SEP-2, SEP-3 and International Index of Erectile Function-Erectile Function (IIEF-EF) domain scores. Adverse events were recorded. Duration of erection (least squares mean ± s.e.) leading to successful intercourse was statistically superior in men receiving vardenafil versus placebo (12.8±1.0 versus 5.5±1.0 min; po0.001 in ENDURANCE and 10.0±0.8 versus 3.4±0.8; po0.001 in the dyslipidemia study), with a difference of 7.4 and 6.6 min, respectively, between treatment groups. Results for SEP-2, SEP-3 and IIEF-EF domain scores were consistent across studies and with stopwatch-assessed measures for duration of erection. Vardenafil was well tolerated. Duration of erection leading to successful intercourse is an important indicator of the efficacy of ED treatment. The stopwatch approach offers an alternative, precise and reproducible measure of efficacy. We propose this approach as a potential new paradigm for assessing the efficacy of ED treatments.
Introduction
ED is a common disorder that affects more than 150 million men worldwide. 1, 2 It is expected that between 1995 and 2025 the prevalence of ED worldwide will have increased by more than 110%. 3 Despite heightened awareness among clinicians and men regarding ED and its treatment options, a reluctance to discuss ED on both the part of the patient and the clinician results in underdiagnosis and undertreatment. 4, 5 Up to 70% of men with ED go untreated 6 and only 58% of men with self-reported ED sought medical attention in a study evaluating the prevalence of ED in the general population. 7 However, the increasing awareness regarding the close association between ED and underlying cardiovascular disease may prompt healthcare professionals to view ED differently. 5, [8] [9] [10] [11] [12] A large body of evidence has accumulated demonstrating that ED and cardiovascular disease share common risk factors, such as diabetes mellitus, hypertension, smoking, dyslipidemia and a sedentary lifestyle. [13] [14] [15] [16] [17] [18] Because endothelial dysfunction is common in ED and these comorbidities, and because ED seems to occur before the onset of cardiovascular symptoms, recent studies have suggested that ED could be considered a potential marker for underlying vascular disease processes. [13] [14] [15] [16] [17] [18] [19] [20] Therefore, early detection of ED may offer clinicians a unique interventional opportunity to address underlying cardiovascular health concerns in men presenting with ED. [13] [14] [15] [16] [17] [18] This stresses the importance of proactively inquiring about ED during annual checkups as part of the overall wellness in men's health.
The PDE-5 inhibitors, vardenafil, 21 sildenafil 22 and tadalafil, 23 remain the safe and effective firstline therapy for ED in men with no contraindications to their use. 24, 25 Although there are few headto-head trials comparing these oral agents, their efficacy and relatively high overall cardiovascular safety profile have been demonstrated in the general population of men with ED [26] [27] [28] [29] as well as special populations, such as men with diabetes mellitus, spinal cord injury, postradical prostatectomy, depression, hypertension and dyslipidemia. [30] [31] [32] [33] [34] [35] [36] [37] The efficacy of PDE-5 inhibitors has usually been assessed by subjective data obtained through validated questionnaires and patient diaries. Questionnaires include the erectile function domain of the International Index of Erectile Function (IIEF-EF), Sexual Encounter Profile question-2 (SEP-2) ('Were you able to insert your penis into your partner's vagina?') and SEP-3 ('Did your erection last long enough for you to have successful intercourse?'), as well as a global assessment question ('Has the treatment you have been taking over the past 4 weeks improved your erections? Yes/No'). Although these subjective measures are useful in research and regulatory settings, they may fail to provide fully objective quantitative and practical data that would be easily understood by non-specialist clinicians and patients. In addition, a quantitative and more objective approach than self-assessment has the potential to serve as a tool for more direct efficacy comparisons in clinical trials.
Such a quantitative and objective method was recently described. Using a stopwatch as an assessment tool, this alternative method provided a reproducible measure of duration of erection leading to successful intercourse in a general population of men with ED undergoing therapy with vardenafil (the ENDURANCE study). 38 This was the first study in which a stopwatch approach was used to measure duration of erection leading to successful intercourse versus placebo as a primary efficacy end point. The same stopwatch approach was also used as a secondary end point to evaluate the efficacy of either on-demand, flexible-dose vardenafil or placebo in a population of men with ED and a higher proportion of comorbidities, all of whom had received a diagnosis of dyslipidemia and required statin therapy (the dyslipidemia study). 39 This paper highlights the results of these two prospective studies. In addition, it highlights the consistency of data obtained across studies using this approach, and their validation with respect to the more traditional self-assessment questionnaires. Stopwatch-assessed duration of erection offers an alternative, more precise outcome-based measurement, more easily interpreted by clinicians and patients. The continuous nature of the stopwatchderived end points may also be a more sensitive method to measure the severity of underlying ED and subsequent treatment response, at least for erection maintenance.
Subjects and methods

Study design
Stopwatch-assessed duration of erection leading to successful intercourse was the primary end point in the ENDURANCE study and one of the secondary end points in the dyslipidemia study. Other efficacy measures, including the SEP-2 and SEP-3 responses and IIEF-EF domain scores, were primary efficacy end points in the dyslipidemia study and secondary end points in the ENDURANCE study. Characteristics of both studies are summarized in Table 1 and methodologies are fully described in Rosenberg et al. 38 and Miner et al. 39 Of note, ENDURANCE was a fixed-dose (10 mg), 4-week crossover study, whereas the dyslipidemia study used a flexible-dose (5/10/20 mg), 12-week parallel group design. Both were randomized, placebo controlled and double blind. Both studies used the standard 4-week treatment-free run-in period to confirm that subjects had ED according to accepted definitions. Subjects with a previous clinical diagnosis of premature ejaculation were excluded. However, premature ejaculation could not be definitively excluded solely on stopwatch data obtained during the untreated run-in period. This would require additional assessments that were not prospectively performed and were beyond the scope of both studies. Preliminary analysis of data from the run-in period revealed that men with untreated ED frequently had sexual encounters associated with a short duration of erection (o1-2 min); however, these attempts were predominantly not accompanied by ejaculation and are thus not consistent with premature ejaculation.
Subjects received an electronic handheld diary at the screening visit. The diary was used to record information about medication intake and sexual activity between visits. If the subject initiated sexual activity with the intention of intercourse, which then resulted in some enlargement of the penis, he was directed to respond to SEP-2 and SEP-3, and to record the duration of erection in minutes and seconds. A stopwatch was used in both studies to precisely measure duration of erection. The EN-DURANCE study protocol specified that the subject was to activate the stopwatch, whereas the dyslipidemia study protocol did not specify which partner was to activate the stopwatch. How intercourse was performed or whether intercourse even occurred was not prespecified. Duration of erection was defined as the time from erection perceived hard enough for penetration (start stopwatch) until withdrawal from the partner's vagina (stop stopwatch).
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Note that the duration of erection measure as defined is distinct and should not be confused with the measure of intravaginal ejaculatory latency time.
Depending on the specifics of an individual sexual intercourse attempt, such as whether or not ejaculation occurred, intravaginal ejaculatory latency time may be a subset of the duration of erection as defined.
The analysis of duration of erection leading to successful intercourse used a subject's median duration of erection value from all attempts made over weeks 0-12. By definition, duration of erection values were taken only from attempts that led to successful intercourse (SEP-3: 'Did your erection last long enough for you to have successful intercourse?' ¼ 'Yes'), and an imputed duration of erection value of zero was used for attempts leading to unsuccessful intercourse (SEP-3 ¼ 'No'). This approach thus accounted for the occurrence of unsuccessful attempts while still analyzing and reporting duration of erection times that were valuable to the subject, that is, attempts that resulted in successful intercourse.
The duration of erection regardless of the SEP-3 response was also analyzed. This end point used the subject's median duration of erection taken from all attempts regardless of the SEP-3 response and allowed all reported values of duration of erection to be compared between treatment groups. Clinically, this translates to simply analyzing the reported duration of erection times, regardless of whether or not they are attached to a successful attempt at intercourse, and provides a more physiologic perspective on what was observed. This analysis is particularly useful in interpreting the change from baseline data because it eliminates the influence of imputed zero values.
Safety
Safety was evaluated throughout the course of the two studies by assessing adverse events (AEs), clinical chemistry, hematology, 12-lead electrocardiogram and vital signs.
Statistical methods
In the ENDURANCE study, responses for each treatment were compared by a mixed-effects model fitting terms for sequence, period, subject within sequence and treatment. The subject was fitted as a random effect. A point estimate and corresponding 95% confidence interval were constructed for the difference between treatments in duration of erection leading to successful intercourse. Similar mixed-effects models were also used for the continuous secondary efficacy end points.
In the dyslipidemia study, comparisons between treatments were conducted using analysis of covariance (controlling for baseline and center). Similar analysis of covariance models were also used for analysis of secondary end points. No adjustments for multiple comparisons were made for the secondary end point analyses. Detailed statistical methods are provided in Rosenberg et al. 38 and Miner et al. 39 
Results
The number of subjects studied and how the populations compared across the two studies are summarized in Table 1 . The subjects in the EN-DURANCE study were younger and had less severe ED as compared with those in the dyslipidemia Stopwatch-assessed duration of erection MT Rosenberg et al study, and thus probably reflect a more 'general' ED population. Overall, a much higher number of subjects with ED in the dyslipidemia study had concomitant comorbidities, such as hypertension (61 versus 32%) and type 1 or 2 diabetes (39 versus 7%), compared with those in the ENDURANCE study and was therefore a potentially more treatment-refractory population. This is likely because of the dyslipidemia study requiring that condition at baseline (100%), whereas the incidence of dyslipidemia was only 28% in ENDURANCE.
Duration of erection leading to successful intercourse, as measured by SEP-3 A total of 191 men participating in the ENDURANCE study 38 were included in the intent-to-treat population. During the 4-week treatment period, the least squares (LS) mean duration of erection leading to successful intercourse was statistically superior in men when treated with vardenafil versus when treated with placebo (12.8 ± 1.0 versus 5.5 ± 1.0 min). Thus, mean duration of erection was 7.4 min longer with vardenafil compared with placebo (95% confidence interval 5.0-9.7; po0.001) ( Table 2) .
The same stopwatch approach was used in a large prospective study in which 100% of the population had both ED and dyslipidemia (the dyslipidemia study). 39 A total of 386 men participating in this study, 35% of whom had moderate ED and 42% severe ED, were included in the intent-to-treat population. During the 12-week treatment period, men receiving flexible-dose vardenafil reported adjusted mean duration of erection leading to successful intercourse of 10.0 min compared with 3.4 min in those receiving placebo (po0.001). This represents a difference of 6.6 min in favor of vardenafil (Table 2) .
Change from baseline in duration of erection leading to successful intercourse In both the studies, change from baseline in duration of erection leading to successful intercourse was analyzed using the same method as in the primary analysis. In the ENDURANCE study, change from baseline in duration of erection leading to successful intercourse was 12.2 ± 1.0 min in men receiving vardenafil versus 4.8±1.0 min when treated with placebo (LS mean±s.e.), a difference of 7.4 min between treatments (95% confidence interval 5.0-9.7; po0.001) ( Table 2 ).
In the dyslipidemia study, change from baseline in duration of erection leading to successful intercourse was 9.5 ± 0.8 min in men receiving vardenafil and 2.8±0.8 min in men taking placebo (LS mean ± s.e.), a difference of 6.6 min between the two groups (po0.001) ( Table 2) .
Duration of erection regardless of SEP-3 response
In the ENDURANCE study, duration of erection regardless of the SEP-3 response was also significantly greater in men receiving vardenafil (13.6 ± 1.0 min) compared with when receiving placebo (7.6 ± 1.0 min) (po0.001), corresponding to a difference in LS mean of 6.0 min (95% confidence interval 3.8-8.2). Change from baseline in duration of erection regardless of the SEP-3 response was 10.3±1.0 min in men receiving vardenafil versus 4.3 ± 1.0 min when receiving placebo (po0.001), a difference of 6.0 min in favor of vardenafil (Table 2 ).
In the dyslipidemia study, duration of erection regardless of the SEP-3 response was 11.2±0.8 min in men receiving vardenafil compared with 4.6±0.8 min in men receiving placebo. Change from baseline in duration of erection leading to successful (Table 2) .
Stopwatch-assessed duration of erection results were consistent with traditional subjective self-assessment measures Traditional efficacy measures (SEP-2, SEP-3 and IIEF-EF domain score) used as secondary end points in the ENDURANCE study and as primary end points in the dyslipidemia study showed significant improvement in erectile function with vardenafil versus placebo (Table 3 ). These improvements versus placebo were statistically significant and clinically relevant, both in a general population of men with ED and in the more refractory population of men with both ED and dyslipidemia. Data obtained for these efficacy measures were consistent across the two studies and with results obtained for duration of erection. These traditional measures indirectly served as internal controls in the two studies. Stopwatchassessed duration of erection obtained in the ENDURANCE study was shown to be highly correlated with the SEP-2 and SEP-3 question responses and IIEF-EF domain scores in another analysis of data from the ENDURANCE study. 40 
Safety
Consistent with previous studies, vardenafil was well tolerated in both studies. Most AEs were mild to moderate in intensity, with headache and flushing being the most frequently reported. A more detailed discussion of treatment-emergent AEs and serious AEs was provided in Rosenberg et al. 38 and Miner et al. 39 
Discussion
In the current literature, the efficacy of oral PDE-5 agents in the treatment of ED is largely based on subjective self-assessment questionnaires. [28] [29] [30] The ENDURANCE and dyslipidemia studies introduce a new precise measure of efficacy, namely, duration of erection accurately timed with a stopwatch. Both the studies demonstrate that the change from baseline in duration of erection leading to successful intercourse in men receiving vardenafil versus placebo is greater than threefold. Several observations can be made from the comparison of the two studies in Table 2 . First, baseline data were similar in all groups in both the studies. This suggests a substantial reliability of the stopwatch measure and attests to its reproducibility in men with ED, regardless of whether the person who activates the stopwatch (subject or partner) is specified. Second, the fact that Table 3 Efficacy results from the ENDURANCE and dyslipidemia studies: standard end points Change from baseline (LS mean ± s.e.) 3.1 ± 0.5 10.2 ± 0.5 2.6 ± 0.6 9.8 ± 0.6 D In LS mean (95% CI) 7.1 (5. It may be that duration of erection is a sign of vascular health, and therefore the first sign of endothelial cell impairment in the penile vasculature is the inability to sustain an erection. ED has long been considered a disease of endothelial cell dysfunction; 15, 16, 18, 19 perhaps, the decreased ability to maintain an erection offers an earlier clue of this evolution. Both Miner 13 and Thompson et al. 17 have noted a 'window of opportunity' for identifying ED and its subsequent cardiac risk. Obviously, a larger 'window' would be most desirable for the patient and provider. Is it possible that decreasing duration of erection is the first noticeable manifestation of an evolving endothelial disease? Would the patient who states that his erections do not last 'as long as they used to' be giving the provider a clue as to the worsening of his cardiovascular status? Would it be easier for a patient to notice or a physician to elicit the ED discussion, if the conversation was based on a practical finding like change in duration in minutes and not study end points that are more appropriately discussed in professional forums?
Is it possible that males learn to adapt to this decreasing duration of erection by ejaculating sooner or lessening foreplay, and focusing solely on penile-vaginal penetration? This can potentially be referred to as 'opportunistic ejaculation'. If the patient knows that he has a limited amount of time before detumescence, then a faster penetration and ejaculation becomes essential. An extreme example would be the patient who has been erroneously labeled as a 'premature ejaculator' when, in fact, he has severe endothelial dysfunction and is only able to maintain an erection for a short period of time at best. In the past, this patient has been excluded from ED studies because of the possibly misguided view that he suffers from premature ejaculation. This patient can easily be visualized as a patient with metabolic syndrome, multiple medical issues and essentially no cardiac reserve. He has learned to be minimally active during sexual encounters to prevent coronary steal 41, 42 and loss of erection. However, in his case, the excitement itself increases his cardiac needs and he must ejaculate quickly, as loss of penile blood flow is imminent.
ED is defined as the inability to obtain or maintain an erection for satisfactory sexual intercourse. 43 Perhaps, a better definition should include what is considered an adequate maintenance or duration of erection. According to Corty and Guardiani, 44 an adequate duration of erection for satisfactory sexual intercourse is 3-7 min, and a desirable duration of erection should be 7-13 min. If that is true, a shorter routine duration may represent the earlier clue of cardiovascular disease risk. This makes sense, as ED does not simply occur overnight; instead, it develops over a period of time in the same manner as most cardiovascular disease does. It is thus reasonable to think that decreasing duration of erection may be a precursor to cardiovascular disease. In the same light, as 'hardness' of erection may also be a 'window' into endothelial dysfunction, 'duration of erection' may add specificity to that window. A change in the patient's perceived hardness may be a hint of cardiovascular issues to come. The next generation of studies should probably go back to the original definition of ED and note the risks identified with changes in obtaining adequate rigidity and maintaining appropriate duration.
Another question that could be raised regarding duration of erection observed in both the Rosenberg et al. 38 and Miner et al. 39 studies is whether any of the other PDE-5 inhibitors (sildenafil and tadalafil) would have a similar effect. Does the degree of receptor affinity matter, or is a greater receptor affinity necessary to obtain such an effect? Logically, a substance with greater affinity for a given receptor at comparable concentrations should have a greater effect; however, further studies are needed to demonstrate that. As vardenafil, sildenafil and tadalafil have different affinities for the PDE-5 receptor, only a crossover study may demonstrate the causal relationship between greater receptor affinity and greater efficacy of one agent compared with the other. The duration of erection end points certainly could provide a more sensitive and reproducible way to compare the effects of pharmacologic agents in any head-to-head studies, in addition to SEP-2, SEP-3 or IIEF-EF, as they are more capable of detecting smaller, clinically relevant changes in treatment response in an objective fashion.
Conclusion
The duration of erection leading to successful intercourse as measured by the stopwatch method is of paramount importance as an indicator of the efficacy of ED treatment. The inability to maintain an erection sufficient for satisfactory sexual performance has been in the definition of ED for a long time. Showing the robust and reproducible effect of vardenafil using this new parameter is 'science catching up with common sense'. We propose the study of duration of erection by use of a stopwatch as not only an efficacy parameter for which all ED drugs can be measured, but also as a potential future tool for identifying early endothelial dysfunction in the setting of suspected vascular disease.
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